Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.50 |
| ▸ | STS | P08842 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23727386 | 0.93 | HPGD (0.68) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL18519689 | 0.93 | HPGD (0.68) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL10233234 | 0.89 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL845563 | 0.89 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL13804048 | 0.89 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL26608596 | 0.89 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL27530648 | 0.89 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL26351284 | 0.87 | GPR119 (0.54) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL28195249 | 0.87 | HPGD (0.68) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL14849627 | 0.86 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118147098-B | Leucine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis | 江南大学 | 2025-04-25 | — | — | CN | claimed |
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | claimed |
| CN-113045484-B | Preparation method of 2-amino-2- (1-methyl-4-piperidinyl) propane-1-ol | 南京药石科技股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-113045484-A | Preparation method of 2-amino-2- (1-methyl-4-piperidyl) propane-1-alcohol | 南京药石科技股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-102775343-A | Preparation method for 1-N-BOC-4-acetyl piperidine | LNK BIO WUXI PHARMACEUTICALS CO LTD | 2012-11-14 | — | — | CN | claimed |
| CN-102351780-A | Method for synthesizing 1-tert-butoxycarbonyl-4-acetylpiperidine | LANZHOU WOFENG BIOTECHNOLOGY CO LTD | 2012-02-15 | — | — | CN | claimed |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| CN-121895218-A | Method for preparing 1-N-Boc-4-acetylpiperidine | 尚科生物医药（上海）有限公司 | 2026-04-21 | — | — | CN | disclosed |
| CN-121895218-A | Method for preparing 1-N-Boc-4-acetylpiperidine | 尚科生物医药（上海）有限公司 | 2026-04-21 | — | — | CN | disclosed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-0946164-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946165-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5952341-A | VITRONECTIN RECEPTOR ANTAGONISTS FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING RESTENOSIS, DIABETIC RETINOPATHY, TUMOR, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5919792-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998018461-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998018460-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | HPGD 2048/4885RECQL 1005/4885PTPN2 2451/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | HPGD 2427/4885RECQL 2122/4885PTPN2 2224/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | HPGD 4491/4885RECQL 1018/4885PTPN2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.